Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow QTTB by emailGet an email when QTTB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about QTTB, unsubscribe in one click. Privacy
📣 What QTTB Says Is Next
first half of 2027 · “Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in the first half of 2027 and additional development opportunities being evaluated.”
Company press release, Aug 5, 2026 · SEC filing
second half of 2027 · “Q32 Bio anticipates data from the Part B OLE in the second half of 2027.”
Company press release, Aug 5, 2026 · SEC filing
1H27 · “Q32 to engage with FDA on proposed registration- SIGNAL-AA Part B directed program with plans to initiate in 1H27”
Company press release, Jul 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full QTTB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QTTB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.